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Abstract
Background: Ras is an area of intensive biochemical and genetic studies and characterizing downstream
components that relay ras-induced signals is clearly important. We used a systematic approach, based on
DNA microarray technology to establish a first catalog of genes whose expression is altered by ras and,
as such, potentially involved in the regulation of cell growth and transformation.
Results: We used DNA microarrays to analyze gene expression profiles of rasV12/E1A-transformed
mouse embryonic fibroblasts. Among the ~12,000 genes and ESTs analyzed, 815 showed altered
expression in rasV12/E1A-transformed fibroblasts, compared to control fibroblasts, of which 203
corresponded to ESTs. Among known genes, 202 were up-regulated and 410 were down-regulated. About
one half of genes encoding transcription factors, signaling proteins, membrane proteins, channels or
apoptosis-related proteins was up-regulated whereas the other half was down-regulated. Interestingly,
most of the genes encoding structural proteins, secretory proteins, receptors, extracellular matrix
components, and cytosolic proteins were down-regulated whereas genes encoding DNA-associated
proteins (involved in DNA replication and reparation) and cell growth-related proteins were up-regulated.
These data may explain, at least in part, the behavior of transformed cells in that down-regulation of
structural proteins, extracellular matrix components, secretory proteins and receptors is consistent with
reversion of the phenotype of transformed cells towards a less differentiated phenotype, and up-regulation
of cell growth-related proteins and DNA-associated proteins is consistent with their accelerated growth.
Yet, we also found very unexpected results. For example, proteases and inhibitors of proteases as well as
all 8 angiogenic factors present on the array were down-regulated in transformed fibroblasts although they
are generally up-regulated in cancers. This observation suggests that, in human cancers, proteases,
protease inhibitors and angiogenic factors could be regulated through a mechanism disconnected from ras
activation.
Conclusions: This study established a first catalog of genes whose expression is altered upon fibroblast
transformation by rasV12/E1A. This catalog is representative of the genome but not exhaustive, because
only one third of expressed genes was examined. In addition, contribution to ras signaling of post-
transcriptional and post-translational modifications was not addressed. Yet, the information gathered
should be quite useful to future investigations on the molecular mechanisms of oncogenic transformation.
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Background
Cancer is a disease caused by multiple genetic alterations
that lead to uncontrolled cell proliferation. This process
often involves activation of cellular proto-oncogenes and
inactivation of tumour-suppressor genes. One of the ear-
liest and most potent oncogenes identified in human can-
cer is the mutant ras [1,2]. Ras family of proto-oncogenes
encodes small GTP-binding proteins that transduce mi-
togenic signals from tyrosine-kinase receptors [reviewed
in [3]]. In vitro, oncogenic ras efficiently transforms most
immortalized rodent cell lines but fails to transform
mouse primary cells [4]. However, ras can transform pri-
mary mouse cells by cooperating with other oncogenic al-
terations such as overexpression of c-Myc, dominant
negative p53, D-type cyclins, Cdc25A and Cdc25B, or loss
of p53, p16 or IRF-1 [5–7]. Several viral onco-proteins can
also cooperate with ras, for example SV40 T-antigen, ade-
novirus E1A, human papillomavirus E7 and HTLV-1 Tax
[reviewed in [6,7]]. When expressed alone in primary
cells, most of these alterations facilitate their immortaliza-
tion [7]. Oncogenic transformation of primary cells by co-
expression of ras and immortalizing mutations constitutes
a model of multistep tumorigenesis that has been repro-
duced in animal systems [reviewed in [8,9]].
Ras has been an area of intensive biochemical and genetic
studies [10]. These studies helped to characterize down-
stream signaling events and components that relay ras-in-
duced mitogenic signals to the ultimate transcription
factors which regulate expression of genes involved in cell
growth and transformation. Downstream signaling elicit-
ed by the oncogenic form of Ras protein impairs regula-
tion of gene expression with eventual disruption of
normal cellular functions. Downstream transcription fac-
tors were found essential for ras-mediated cell transforma-
tion [11–13]. However, compared with our knowledge on
ras signaling events, little is known on target genes in-
volved in the phenotypic changes resulting from ras acti-
vation, such as cell transformation. Thus, identification of
genes whose expression is altered during ras-mediated cell
transformation would provide important information on
the underlying molecular mechanism. In the present
work, we used DNA microarray technology to analyze
gene expression profiles of rasV12/E1A-transformed pri-
mary mouse embryonic fibroblasts (MEFs), in order to
identify genes whose expression is transformation-de-
pendent.
Results
Analysis of gene expression changes after rasV12/E1A-
transformation
We used microarray analysis to compare expression pro-
files of ~12,000 genes in normal vs. rasV12/E1A-trans-
formed fibroblasts. Figure 1 shows the phenotypic
changes of the rasV12/E1A-transformed MEFs. With Af-
fymetrix microarray technology, differential expression
values greater than 1.7 are likely to be significant, based
on internal quality control data. We present data which
use a more stringent ratio, restricting our analysis to genes
that are overexpressed or under-expressed at least 2.0 fold
in rasV12/E1A-transformed fibroblasts relative to the emp-
ty retrovirus-transduced MEFs. We summarize the high-
lights below and present the full profile in Figure 2.
Among the ~12,000 genes and ESTs analyzed, expression
of 815 showed to be altered by at least 2.0 fold in the
rasV12/E1A-transformed fibroblasts, of which 203 corre-
sponded to ESTs. Among known genes, 202 were up-reg-
ulated (Table 1)(see Additional file 1) whereas 410 were
down-regulated (Table 2)(see Additional file 2) by rasV12/
E1A-transformation. It is interesting to note that about
one half of genes encoding transcription factors, signaling
proteins, membrane proteins, channels, or apoptosis-re-
lated proteins was up-regulated whereas the other half
was down-regulated (Figure 2). However, after rasV12/
E1A-transformation most of genes encoding structural
proteins, secretory proteins, receptors, proteases, protease
inhibitors, extracellular matrix components, proteins in-
volved in angiogenesis and cytosolic proteins, were down-
regulated whereas genes encoding DNA-associated pro-
teins (involved in DNA replication and reparation) and
cell growth-related proteins were up-regulated (Figure 2).
These data may explain, at least in part, the behavior of
transformed cells. For example, down-regulation of struc-
tural proteins, extracellular matrix components, secretory
proteins and receptors is consistent with reversion of the
phenotype of transformed cells towards a less differentiat-
ed phenotype and up-regulation of cell growth-related
proteins and DNA-associated proteins is consistent with
their accelerated growth.
Transcription factors
57 genes encoding transcription factors were up-regulated
and 45 down-regulated by rasV12/E1A-transformation.
The most strongly activated genes corresponded to the
homeobox protein SPX1 (39 fold), myb proto-oncogene
(25 fold) and the paired-like homeodomain transcription
factor (19 fold), whereas the most repressed were the os-
teoblast specific factor 2 (123 fold), the p8 protein (51
fold), the H19 mRNA (21 fold) and the early B-cell factor
(20 fold).
Structural proteins
Expressions of 10 genes encoding structural proteins were
up-regulated in MEFs-transformed cells, 44 being down-
regulated. The most important up-regulation was ob-
served for cytokeratin (26 fold) and desmoplakin I (17
fold), the strongest down-regulations for smooth muscle
calponin (115 fold), transgelin (49 fold), debrin (41
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Figure 1
A. Expression of RAS was verified by immunoblot analysis in MEFs transduced with pBabe (control) or pBabe-rasV12/E1A 
(transformed) retroviruses. B. Morphological aspect of the pBabe and pBabe-rasV12/E1A transduced mouse embryonic fibrob-
lats. C. Anchorage-independent growth of the rasV12/E1A transformed MEF. Fifty thousand cells were plated on 0.6% agar in 
DMEM-10% FCS and overlaid on 0.6% agar in the same medium. Photomicrographs were taken 10 days after plating. D. rasV12/
E1A transformed MEF induce tumor formation. One million of pBabe and pBabe-rasV12/E1A transduced mouse embryonic 
fibroblast were injected in 200 µl PBS as xenografts in nude mice. Representative mice at day 18.
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fold), p50b (35 fold) and vascular smooth muscle alpha-
actin (34 fold).
Signaling factors
36 genes encoding proteins involved in numerous signal-
ing pathways were up-regulated and 79 down-regulated in
rasV12/E1A-transformed MEFs. The EGP314 precursor (al-
so known as the calcium signal transducer 1) was found
25 fold up-regulated, whereas the cysteine rich intestinal
protein (41 fold) and ASM-like phosphodiesterase 3a (31
fold) were the most strongly down-regulated genes.
Secretory proteins
Only one gene, encoding the transforming growth factor
alpha, was detected as up-regulated (3 fold) in trans-
formed cells. By contrast, expressions of 54 secretory pro-
teins were repressed after rasV12/E1A-transformation. The
most affected genes were those encoding cholecystokinin
(112 fold), serum amyloid A3 (85 fold), PRDC (58 fold),
insulin-like growth factor binding protein 5 (41 fold),
gremlin (36 fold), follistatin (33 fold), the small induci-
ble cytokine subfamily B (27 fold), cytokine SDF-1-beta
(23 fold) and the small inducible cytokine A7 (22 fold).
Receptors
8 receptors were up-regulated and 38 down-regulated in
transformed fibroblasts. Overexpression was observed for
acetylcholine receptor beta (8 fold), tyrosine kinase recep-
tor (3 fold), growth hormone releasing hormone receptor
(3 fold), semaphorin M-sema G (3 fold) and amphiregu-
lin (2 fold). Strongest down-regulations were found for
integrin alpha 5 (43 fold), transient receptor protein 2 (19
fold), retinoic acid receptor alpha (14 fold), retinoic or-
phan receptor 1 (11 fold) and platelet derived growth fac-
tor receptor (12 fold).
Protein synthesis
3 genes involved in protein synthesis (BRIX, nucleolin, ri-
bosomal protein L44 and SIK similar protein) were over-
expressed and 2 (ribosomal protein S4X and ribosomal
protein L39) were down-regulated, suggesting that pro-
tein synthesis is not strongly affected by transformation.
Proteases and protease inhibitors
Only the kallikrein B protease and the elafin-like protein
II protease inhibitor were up-regulated (3 and 2 fold re-
spectively) after rasV12/E1A-transformation. By contrast,
16 proteases and 7 protease inhibitors were found re-
pressed in transformed MEFs. The tolloid-like (41 fold)
and meltrin beta (33 fold) were proteases most down-reg-
ulated and the tissue factor pathway inhibitor 2 (44 fold)
and the plasminogen activator inhibitor (31 fold) were
the most affected protease inhibitors.
Membrane proteins
15 genes encoding membrane proteins were up-regulated
and 21 were down-regulated. Histocompability 2, D re-
gion locus, (16 fold) and melanoma differentiation asso-
ciated protein (9 fold) were the most overexpressed genes,
whereas Thy-1.2 glycoprotein (36 fold), cadherin 11 (14
fold) and vascular cell adhesion molecule 1 (13 fold) were
the most repressed.
Extracellular matrix
Laminin gamma 1 (20 folds) and entactin-2 (6 folds)
were the two extracellular matrix encoding genes found
up-regulated during transformation, whereas 24 genes
were down-regulated. Among them, procollagen type VI,
alpha 1 (121 folds), procollagen type III, alpha 1 (56
folds), procollagen type I, alpha 1 (44 folds), procollagen
type I, alpha 2 (37 folds), collagen type VI, alpha 3
Figure 2
Gene expression changes after rasV12/E1A-transformation. 
Number of genes up-regulated or down-regulated were 
grouped by function (Transcription factors, structural pro-
teins, signaling, secretory proteins, receptors, protein syn-
thesis, proteases, protease inhibitors, membrane proteins, 
extracellular matrix, enzymes, DNA-associated proteins, 
cytosolic proteins, channels, cell growth-associated proteins, 
angiogenesis, apoptosis and unknown function). Bars repre-
sent the number of genes in each group.
Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/19
Page 5 of 10
(page number not for citation purposes)
subunit (21 folds) and decorin (19 folds) were the most
affected.
Enzymes
Twelve enzymes involved in cellular metabolism were
found overexpressed after rasV12/E1A-transformation and
44 were found down-regulated. The most activated genes
were serine hydroxymethyl transferase 1 (6 fold), acetyl
coenzyme A dehydrogenase (5 fold) and the acetyltrans-
ferase (GNAT) family containing protein (4 fold), where-
as the most repressed genes were lysozyme P (88 fold),
lysyl oxydase (61 fold) and lysozyme M (55 fold). Inter-
estingly, maximal overexpressions were 6, 5 and 4 fold,
whereas down-regulations were 88, 61 and 55 fold indi-
cating that in addition to the fact that more genes were
down-regulated (44 vs. 12), change in expression was also
more important for down-regulated genes.
DNA-associated proteins
25 genes encoding DNA-associated proteins were up-reg-
ulated, whereas no gene of this family was found down-
regulated. The most strongly activated genes were nucleo-
side diphosphate kinase (9 fold), the topoisomerase-in-
hibitor suppressed (7 fold), the helicase lymphoid specific
(6 fold) and the DNA2-like homolog (6 fold).
Cytosolic proteins
Expression of 2 genes encoding cytosolic proteins was ac-
tivated after rasV12/E1A-transformation, whereas expres-
sion of 6 genes was repressed. Genes coding for acyl-CoA-
binding protein (3 fold) and tubulin-specific chaperone
(2 fold) were overexpressed, whereas the most strongly re-
pressed gene was that coding cytochrome P450 (61 fold).
Channels
5 genes encoding channels were up-regulated and also 5
were down-regulated. Chloride channel protein 3 was the
most up-regulated gene (11 fold) and the channel beta-1
subunit (15 fold) was the most down-regulated gene.
Cell growth-associated proteins
As expected for transformed cells which grow more rapid-
ly, 13 genes encoding proteins involved in cell growth
were found overexpressed, whereas only 3 were found
down-regulated in rasV12/E1A-transformed MEFs. The
most activated genes were those coding for cyclin-depend-
ent kinase-like 2 (6 fold) and cell division cycle 7-like 1 (5
fold) whereas the most repressed gene was cyclin D2 (4
fold).
Angiogenesis
Angiogenesis is a key process in carcinogenesis. Contrary
to the expected for a tumoral cell, we were unable to
found angiogenesis-associated genes up-regulated by
rasV12/E1A-transformation. To our surprise, all 8 genes as-
sociated with angiogenesis showing differential expres-
sion were down-regulated. These included genes coding
for thrombospondins 1 (15 fold), 2 (32 fold) and 3 (6
fold), pigment epithelium-derived factor (26 fold), pleio-
trophin (24 fold), GRO1 oncogene (16 fold), angiogenin-
related protein (4 fold) and tumor necrosis factor induced
protein 2 (3 fold).
Apoptosis
8 apoptosis-related genes were up-regulated in trans-
formed MEFs and 3 down-regulated. The p53 apoptosis
effector related to Pmp22 was the most activated gene (19
fold) and death-associated protein 1 gene was the most
under-expressed (4 fold) after transformation.
Unknown function
3 genes encoding proteins without well defined function
were found up-regulated in mutated ras-E1A expressing fi-
broblasts, whereas 8 were found to be down-regulated.
As a proof-of-principle, we verified the relative expression
levels of 11 of these 815 genes by Northern blot analysis.
The following 11 genes were tested : p8, transgelin, serum
amyloid A3, lysyl oxidase, thrombospondin 2, extracellu-
lar superoxide dismutase, biglycan, myb, cytokeratin,
HMG2 and ezrin. In all of them Northern blot data con-
firmed microarray data. The first 7 were down-regulated
in transformed MEFs, the 4 others being overexpressed
(Figure 3).
Discussion
A number of ras-regulated genes have been identified by
studies on immortalized cells or cancer cells expressing
the oncogenic ras [14–21]. However, although these re-
sults are quite interesting, it is important to note that es-
tablished cell lines are frequently subject to genetic and
epigenetic changes that are selected during passaging or
immortalization and may affect ras target-gene expres-
sion. Primary cultures, such as mouse embryonic fibrob-
lasts, do not have that drawback. This is why, to identify
ras target genes, we decided to analyze global gene expres-
sion shortly after retroviral transfer of an ectopic mutated
ras in MEFs. Yet, because activated ras alone induces MEF
senescence instead of transformation, we associated to it
the adenovirus-derived oncogene E1A. The rasV12/E1A
transformation of MEFs (and of other non-immmortal-
ized cells as well) is specific and controlled. Using the Af-
fymetrix technology on ~12,000 genes, we found that
expression of 6.8% of them was significantly modified in
MEFs by rasV12/E1A-transformation. Because oncogenic
transformation of fibroblasts allows tumor development
when cells are injected in the immunocompromised
mouse (see Figure 1), studying target genes of activated ras
should improve our understanding of the molecular
mechanisms by which ras transforms cells and eventually
Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/19
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Figure 3
Confirmation of microarray results by Northern blot analysis. 18S rRNA was used as a loading control. Total RNA isolated 
from pBabe and pBabe-rasV12/E1A transduced MEFs were blotted onto Hybond-N membranes and hybridized with 32P-labeled 
probes as described in Material and Methods section.
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allows tumor formation. It is interesting to note that only
24% of down-regulated and 40% of up-regulated genes
showed strong modification (i.e.: >5 fold change) of its
expression after transformation.
Several examples of genes up- or down-regulated upon ras
transformation have already been reported [22–25].
Present data on systematic analysis of about one third of
the expressed genome confirm those reports while extend-
ing considerably our knowledge of genes activated or re-
pressed by oncogenic ras in association with the E1A
adenoviral protein. Our results may explain the behavior
of transformed cells. For example and as expected, virtual-
ly all of the genes coding for secreted factors or extracellu-
lar matrix component, which are associated with a
differentiated phenotype, were down-regulated. Also,
morphological changes observed after transformation
(see Figure 1), may be explained by the fact that 44 genes
encoding structural proteins were under-expressed. An-
other expected result was that cell growth-related proteins
(involved in the regulation of the cell cycle or inducing
cell proliferation) and DNA-associated proteins (involved
in DNA replication and reparation) were up-regulated in
transformed MEFs, in agreement with their accelerated
growth. Also, it is not a surprise to find an altered expres-
sion for 56 enzymes involved in cell metabolism because,
compared to normal fibroblasts, transformed cells show
accelerated growth, increased migration capacity and
strong morphological changes. These enzymes could be
involved in some of these changes.
Several genes coding for transcription factors (n = 102)
and proteins involved in signaling pathways (n = 115)
were up- or down-regulated suggesting that modification
of the amounts of these factors could be responsible for
the dramatic changes in gene expression observed in
transformed cells. It is interesting to note that approxi-
mately as many transcription factors were up-regulated (n
= 57) as down-regulated (n = 45).
Besides data coherent with previous knowledge, we also
found very unexpected results. For example, we found
that genes coding for proteases and inhibitors of proteases
were strongly down-regulated by rasV12/E1A transforma-
tion. This was surprising since these factors are up-regulat-
ed and strongly involved in tumor progression involving
mutated ras. This observation could suggest that in
human cancers, proteases and protease inhibitors are acti-
vated through a mechanism disconnected from ras activa-
tion. We were similarly surprised by the fact that all 8
angiogenic factors present on the array were found down-
regulated by rasV12/E1A transformation. Like proteases
and inhibitors of proteases, angiogenic factors are in-
volved in tumour progression and still repressed during
rasV12/E1A-mediated transformation. It is therefore high-
ly unlikely that their overexpression reported in several
cancers is controlled by a ras-dependent pathway. Finally,
it was also unexpected that only 5 genes involved in pro-
tein synthesis were up- or under-expressed, suggesting
that protein synthesis is not strongly altered after rasV12/
E1A transformation.
Conclusions
In conclusion, this study of a large number of genes has
identified those whose expression is altered upon fibrob-
last transformation by rasV12/E1A. It is however not ex-
haustive because the analyzed genes are only
representative of the genome (one third of the expressed
genes was examined), and post-transcriptional and post-
translational modifications were not addressed. Yet, infor-
mation gathered should be quite useful to future investi-
gations on the molecular mechanisms of oncogenic
transformation.
Methods
Primary mouse embryo fibroblasts (MEFs)
Primary embryo fibroblasts were isolated from 14.5 day-
old SV129J mouse embryos following standard protocols
[26]. Cell were grown in Dulbecco's modified Eagle's me-
dium (DMEM) supplemented with 10% foetal calf serum,
2 mM L-glutamine, 100 IU/ml penicilin G and 100 µg/ml
streptomycin.
Retroviral infection
Oncogenic ras transforms most immortal rodent cells to a
tumorigenic state, whereas transformation of mouse pri-
mary cells requires either a cooperating oncogene or the
inactivation of a tumour suppressor gene. The adenovirus
E1A oncogene cooperates with ras to transform primary
mouse fibroblasts [7] and abrogates ras-induced senes-
cence [27]. Therefore, we transduced MEFs with the
pBabe-rasV12/E1A retroviral vector which expresses both
the rasV12 mutated protein and the E1A oncogene to ob-
tain transformed fibroblasts. pBabe-rasV12/E1A [described
in ref. [27]] and pBabe (as control) plasmids were ob-
tained from S. Lowe. Bosc 23 ecotropic packaging (106)
cells were plated in a 6-well plate, incubated for 24 hr, and
then transfected with PEI with 5 µg of retroviral plasmid.
After 48 hr, the medium containing the virus was filtered
(0.45 µm filter, Millipore) to obtain the first supernatant.
MEFs were plated at 2 × 105 cells per 35 mm dish and in-
cubated overnight. For infections, the culture medium
was replaced by an appropriate mix of the first superna-
tant and culture medium (V/V), supplemented with 4 µg/
ml polybrene (Sigma), and cells were incubated at 37°C.
As a control, we evaluated the ability of the retroviral vec-
tor to transduce MEFs by using a retroviral vector express-
ing the EGFP under control of the retroviral promoter
located in the long terminal repeat. About 30% of MEFs
expressed high levels of EGFP fluorescence 48 h after
Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/19
Page 8 of 10
(page number not for citation purposes)
transduction (data not shown), indicating that retroviral
vectors are well adapted to our experimental set-up. Retro-
virus-infected cells were selected with puromycin (0.7 µg/
ml). Transformation of MEFs by the pBabe-rasV12/E1A
retroviral vector was evaluated by examining changes in
their morphological aspect, by quantifying expression of
the RAS protein by western blot, by monitoring cell pro-
liferation, colony formation in soft-agar and tumors in
nude mice. In soft-agar assays, pBabe-rasV12/E1A trans-
formed cells formed colonies at high frequency (Figure 1).
Similarly, transformed cells produced tumors in all (3/3)
athymic nude mice when injected subcutaneously, where-
as control MEFs did not (0/3) (Figure 1).
Western blot analysis
One hundred µg of total protein extracted from cells was
separated with standard procedures on 12.5% SDS-PAGE
using the Mini Protean System (Bio-Rad) and transferred
to a nitrocellulose membrane (Sigma). The intracellular
level of RAS was estimated by Western blot using the H-
ras (C-20) polyclonal antibody (1:200) purchased from
Santa Cruz Biotechnology, Inc.
Microarray
Total RNA was isolated by Trizol (Gibco-BRL by Invitro-
gen). Twenty µg of total RNA was converted to cDNA with
SuperScript reverse transcriptase (Gibco-BRL by Invitro-
gen), using T7-oligo-d(T)24 as a primer. Second-strand
synthesis was performed using T4 DNA polymerase and E.
Coli DNA ligase followed by blunt ending by T4 polynu-
cleotide kinase. cDNA was isolated by phenol-chloroform
extraction using phase lock gels (Brinkmann). cDNA was
in vitro transcribed using the T7 BioArray High Yield RNA
Transcript Labeling Kit (Enzo Biochem, New York, N.Y.)
to produce biotinylated cRNA. Labelled cRNA was isolat-
ed using an RNeasy Mini Kit column (Qiagen). Purified
cRNA was fragmented to 200–300 mer cRNA using a frag-
mentation buffer (100 mM potassium acetate-30 mM
magnesium acetate-40 mM Tris-acetate, pH 8.1), for 35
min at 94°C. The quality of total RNA, cDNA synthesis,
cRNA amplification and cRNA fragmentation was moni-
tored by micro-capillary electrophoresis (Bioanalizer
2100 by Bioanalyser 2100, Agilent Technologies). The
cRNA probes were hybridized to an MGu74Av2 Genechip
(Affymetrix, Santa Clara, CA). The MGu74Av2 Genechip
represents ~6,000 sequences of mouse Unigene that have
been functionally characterized and ~6,000 sequences
ESTs clusters. Each sequence in the chip is represented by
32 probes : 16 "perfect match" (PM) probes that are com-
plementary to the mRNA sequence and 16 "mismatch"
(MM) probes that only differ by a single nucleotide at the
central base (more detailed information about the
MGu74Av2 Genechip can be obtained in the web site ht-
tp://www.affymetrix.com. Fifteen micrograms of frag-
mented cRNA was hybridized for 16 h at 45°C with
constant rotation (60 rpm). Microarrays were processed in
an Affymetrix GeneChip Fluidic Station 400. Staining was
made with streptavidin-conjugated phycoerythrin (SAPE)
followed by amplification with a biotinylated anti-
streptavidin antibody and a second round of SAPE, and
then scanned using an Agilent GeneArray Scanner (Agi-
lent Technologies). Expression value (signal) is calculated
using Affymetrix Genechip software MAS 5.0 (for fully de-
scription of the statistical algorithms see http://affyme-
trix.com/support/technical/whitepapers/
sadd_whitepaper.pdf. Briefly, signal is calculated as fol-
low : First, probe cell intensities are processed for global
background. Then, MM value is calculated and subtracted
to adjust the PM intensity in order to incorporate some
measure of non-specific cross-hybridization to mismatch
probes. Then, this value is log-transformed to stabilize the
variance. Signal is output as the antilog of the resulting
value. The 20 probe pairs representing each gene are con-
solidated into a single expression level. Finally, software
scales the average intensity of all genes on each array with-
in a data set. Final value of signal is considered represent-
ative of the amount of transcript in solution.
Housekeeping controls β-actin and GAPDH genes serve as
endogenous controls and are useful for monitoring the
quality of the target. Their respective probe sets are de-
signed to be specific to the 5', middle, or 3' portion of the
transcript. The 3'/5' signal ratio from these probe sets is in-
formative about the reverse transcription and in vitro tran-
scription steps in the sample preparation. Then, an ideal
target in which all transcripts was full-length transcribed
would have an identical amount of signal 3' and 5' and
the ratio would be equal to 1. Differences greater than
three fold between signal at 3' and 5' for these housekeep-
ing genes indicate that RNA was incompletely transcribed
or target may be degraded. Ratio of fluorescent intensities
for the 5' and 3' ends of these housekeeping genes was <2.
Hybridization experiments were repeated twice using in-
dependent cRNA probes synthezised with RNA from two
independent sets of MEF-infected cells. Genes were con-
sidered as differentially expressed when both hybridiza-
tions showed >2 folds change. Data presented in this work
represent the average of both hybridizations. The list of
unchanged genes should be obtained from authors upon
request.
Validation of gene expression profiles by Northern blot 
hybridization
Synthesis of probes: One microgram of total RNA from
MEF cells was subjected to PCR with reverse transcription
using the One Step RT-PCR kit (Gibco-BRL) according to
the manufacturer's protocol to synthezise specific cDNA
probes. PCR were carried out for 32 cycles, each cycle
consisting in a denaturing step for 1 min at 94°C, an
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annealing step for 2 min at 56°C, and a polymerization
step for 2 min at 72°C. Selected RNA species were ampli-
fied using the following primers: p8, sense, 5'-ggagagagca-
gactaggcata-3' and antisense, 5'-gttgctgccacccaagggcat-3';
transgelin, sense, 5'-ccagccagctctgcagatggg-3'and anti-
sense, 5'-gcaggcagatttctgagttc-3'; serum amyloid A3, sense,
5'-ggatgaagccttccattgcc-3' and antisense, 5'-gaagagctacac-
cgccactc-3'; lysyl oxidase, sense, 5'-taaaacgactgtccccaacc-3'
and antisense, 5-tcacggccgttgttagtgta-3'; thrombospondin
2, sense, 5'-aagcccagtcgggcttacgg-3' and antisense, 5-tgct-
ggagctggagccctgc-3'; extracellular superoxide dismutase,
sense, 5'-ccttagttaacccagaaatct-3' and antisense 5'-gtacct-
caaaggtgctcactgg-3'; biglycan, sense, 5'-ggctgctttctgct-
tcacagg-3' and antisense 5'-gcaactgaccatcacctccta-3'; myb
proto-oncogene, sense, 5'-ctaaaccatttcatgaggag-3' and an-
tisense, 5-aacaaatgcaaaattcaccc-3'; cytokeratin, sense, 5'-ct-
ggtctcagcagattgagg-3' and antisense, 5-
ggtaggtggcaatctctgcc-3' ; high mobility group protein 2,
sense, 5'-cgtctgccttctgcctgttttg-3' and antisense 5'-gccctt-
gacacggtatgcagc-3' and ezrin, sense, 5'-caacgaggagaagcg-
gatca-3' and antisense 5'-gtgtgacacctgcctgcagtg-3'.
Specificity of the PCR products was confirmed by direct
DNA sequencing.
Northern blot hybridization: RNA samples (10 µg) were
submitted to electrophoresis on a 1% agarose gel and vac-
uum blotted onto Hybond-N membranes (Amersham).
The filters were hybridized with the 32P-labeled probes for
16 h at 65°C in 5X SSPE (1X SSPE is 180 mM NaCl, 1 mM
EDTA, 10 mM NaH2PO4, pH 7.5), 5X Denhardt solution,
0.5% SDS and 100 µg/ml single stranded herring sperm
DNA. Filters were then washed four times for 5 min at
room temperature in 2X SSC, 0.2% SDS, twice for 15 min
at 50°C in 0.2X SSC, 0.2% SDS, and once for 30 min in
0.1X SSC at 50°C before autoradiography exposure on
Kodak X-Omat films at -80°C from 8 hr to 4 days.
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